Delineating the Complex Genomic Landscape of Multiple Myeloma Using Next-Generation Sequencing (NGS): Progress and Potential to Supersede Traditional Genetic Testing

Affiliations

PMID: 32889805

Abstract

Recent NGS studies in multiple myeloma identified in one step and with comparable high accuracy to the concurrent cytogenomic tests the characteristic IGH translocations and copy number abnormalities. In addition, NGS allowed detection of gene mutations. This unprecedented success of a comprehensive genomic analysis suggests the possibility of replacing the separate tests in current use (cytogenetics, FISH, SNPs microarray and mutation analysis) with a single more efficient NGS assay. Down the road, NGS appears to have the potential to improve routine patient care with the clinical application of a detailed genomic profile.

Similar articles

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.
Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, Ciardiello A, Landau H, Akhlaghi T, Mailankody S, Patel M, Medina-Martinez JS, Arango Ossa JE, Levine MF, Bolli N, Maura F, Dogan A, Papaemmanuil E, Zhang Y, Landgren O.Blood Cancer J. 2019 Dec 11;9(12):101. doi: 10.1038/s41408-019-0264-y.PMID: 31827071 Free PMC article.
Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
Mukherjee S, Sathanoori M, Ma Z, Andreatta M, Lennon PA, Wheeler SR, Prescott JL, Coldren C, Casey T, Rietz H, Fasig K, Woodford R, Hartley T, Spence D, Donnelan W, Berdeja J, Flinn I, Kozyr N, Bouzyk M, Correll M, Ho H, Kravtsov V, Tunnel D, Chandra P.Cancer Genet. 2017 Oct;216-217:128-141. doi: 10.1016/j.cancergen.2017.07.010. Epub 2017 Aug 14.PMID: 29025587
Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders.
Pugh TJ, Fink JM, Lu X, Mathew S, Murata-Collins J, Willem P, Fang M; Cancer Genomics Consortium Plasma Cell Disorders Working Group.Cancer Genet. 2018 Dec;228-229:184-196. doi: 10.1016/j.cancergen.2018.07.002. Epub 2018 Oct 5.PMID: 30393007 Review.
A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.
Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, Cocito F, Bignell G, Chapman MA, Sperling AS, Anderson KC, Avet-Loiseau H, Minvielle S, Campbell PJ, Munshi NC.Blood Cancer J. 2016 Sep 2;6(9):e467. doi: 10.1038/bcj.2016.72.PMID: 27588520 Free PMC article.
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C.Front Oncol. 2020 Feb 25;10:189. doi: 10.3389/fonc.2020.00189. eCollection 2020.PMID: 32181154 Free PMC article. Review.